Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
Kestra Medical Technologies Ltd (KMTS) delivers innovative wearable cardiac solutions through its ASSURE WCD and integrated Cardiac Recovery System. This news hub provides stakeholders with essential updates on the company developments shaping cardiovascular care technology.
Access timely announcements including FDA clearances, clinical trial results, partnership agreements, and financial disclosures. Our curated collection serves investors and healthcare professionals tracking advancements in life-saving wearable defibrillator technology and digital health integration.
Key updates cover regulatory milestones, product enhancements, peer-reviewed study publications, and strategic collaborations. Discover how KMTS continues to address sudden cardiac arrest risks through engineering innovations and evidence-based patient support systems.
Bookmark this page for centralized access to verified corporate communications. Check regularly for developments impacting the wearable medical device sector and KMTS's position within the cardiovascular care market.
Kestra Medical Technologies (Nasdaq: KMTS) reported Q2 FY2026 results for the period ended October 31, 2025: revenue $22.6M (+53% YoY), ASSURE prescriptions 4,696 (+54% YoY), and gross margin 50.6% (vs 39.6% prior year). GAAP net loss was $32.8M and adjusted EBITDA loss was $19.7M. Kestra raised FY26 revenue guidance to $91M (+52% vs FY25). Cash and cash equivalents were $175M as of Oct 31, 2025; the company also received $148M net proceeds from a Dec 4, 2025 public offering.
The company cited commercial expansion, improved revenue cycle management, and a stronger in-network mix as drivers of performance.
Kestra Medical Technologies (Nasdaq: KMTS) will report second quarter fiscal 2026 financial results on Thursday, December 11, 2025. Management will host a conference call at 4:30 p.m. Eastern Time with a live and archived webcast available in the investor relations "Events" section. Participants are encouraged to register on the website at least 10 minutes prior to the call start.
Kestra Medical Technologies (Nasdaq: KMTS) priced an upsized underwritten public offering of 6,000,000 common shares at $23.00 per share, producing expected gross proceeds of $138,000,000.
The company granted the underwriters a 30-day option to buy up to 900,000 additional shares at the offering price less discounts. The offering is expected to close on December 4, 2025, subject to customary closing conditions. A registration statement was declared effective on December 2, 2025.
Kestra Medical Technologies (Nasdaq: KMTS) announced a proposed underwritten public offering of 5,500,000 common shares with a 30-day underwriter option to purchase up to an additional 825,000 shares, subject to market conditions and SEC effectiveness of the registration statement (as of Dec 1, 2025).
The company intends to use proceeds to support sales and marketing, ongoing commercialization, further fund research, development and clinical studies, and for working capital and general corporate purposes. All offered shares are being sold by Kestra. Bookrunners include BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs and Wells Fargo Securities. The offering may not occur and terms may change.
Kestra Medical Technologies (Nasdaq: KMTS) reported preliminary Q2 fiscal 2026 results for the quarter ended October 31, 2025, showing continued commercial momentum in the wearable defibrillator market. Revenue is expected to be $22.2–$22.6M, up ~52% at the midpoint versus prior year. Gross profit is expected to be $11.0–$11.4M and gross margin is expected near 50.0% versus 39.6% prior year. Loss from operations is expected to be $31.6–$32.0M. Cash and cash equivalents are expected to be approximately $175M. Results are preliminary and subject to adjustment; final results will appear in the Form 10-Q filed in December 2025.
Kestra Medical Technologies (Nasdaq: KMTS) announced primary results from ACE-PAS, the largest prospective real-world study of wearable defibrillators, presented at AHA Scientific Sessions 2025.
The study enrolled 21,612 patients and showed 100% successful conversion of VT/VF events versus the prespecified goal; an inappropriate-shock rate of 0.0065 per patient-month; 94% of patients had no false positive shock alarms; 2.6% experienced at least one life-threatening VT/VF; ASSURE detected 4.2% high-rate atrial fibrillation (35% newly diagnosed) and 0.3% severe bradycardia/asystole. Median wear time exceeded 23 hours/day, with one-third using the device beyond 90 days.
Kestra Medical Technologies (Nasdaq: KMTS) will present late-breaking results from the ACE-PAS trial at the American Heart Association Scientific Sessions 2025 on Nov 10, 2025 at 8:44 a.m. CT (Session 211–213).
ACE-PAS is a post-approval, real-world evaluation of the next-generation ASSURE wearable cardioverter defibrillator, enrolling more than 20,000 patients across the U.S., and is described as the largest prospective WCD study to date. Primary endpoints include overall shock conversion success and inappropriate shock rate; additional measures: first shock conversion success, median daily wear time, and false alarm rate.
Kestra will also host live demonstrations and an immersive in-booth experience at booth #4617 during AHA Nov 7–10, highlighting its Cardiac Recovery System and connected care tools.
Kestra Medical Technologies (Nasdaq: KMTS) will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 3:20 p.m. ET.
Investors and interested parties can watch a live webcast and later view a replay on the Kestra Medical Technologies investor relations website.
Kestra Medical Technologies (Nasdaq: KMTS) appointed Timothy Moran as Chief Business Officer, effective November 3, 2025. In the role Moran will lead business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management.
Moran brings over 25 years in medtech, most recently serving as president and CEO at Avertix Medical where he led a launch of a first‑to‑market implantable cardiac device, and previously as CEO of Motus GI Holdings. Management expects Moran to support the company’s commercial ramp, advance payor and provider partnerships, and accelerate adoption of the Cardiac Recovery System and ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis. The company will showcase its Cardiac Recovery System® (CRS) platform, featuring the ASSURE® Wearable Cardioverter Defibrillator at booth #920.
The CRS platform aims to enhance sudden cardiac death protection by combining protective measures with actionable insights during critical heart failure recovery phases. Visitors can experience hands-on demonstrations of the platform, which focuses on strengthening patient-provider connections and supporting vulnerable patients' recovery.
FAQ
What is the current stock price of KESTRA MED TECHNOLOGIES (KMTS)?
What is the market cap of KESTRA MED TECHNOLOGIES (KMTS)?
